Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hip fractures present some of the biggest challenges facing patients and healthcare systems. Worldwide, there are currently 1.3 million hip fractures per year, projected to rise to more than six million by 2050. The World Hip Trauma Evaluation (WHiTE) platform trial will provide randomized evidence dealing with the clinical and cost-effectiveness of interventions to improve outcomes for patients with a fragility fracture of the hip. The previous WHiTE cohort multiple-embedded trials' model was highly successful in delivering evidence to inform national and international policy and practice guidelines. This annotation addresses two questions: why change to a platform trial design? And what are the potential advantages and disadvantages of trials which use newer methodologies?

Original publication

DOI

10.1302/0301-620X.107B8.BJJ-2024-1687.R1

Type

Journal article

Journal

Bone joint j

Publication Date

01/08/2025

Volume

107-B

Pages

772 - 776

Keywords

Humans, Randomized Controlled Trials as Topic, Hip Fractures, Research Design, Cost-Benefit Analysis